Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 4 of 71.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-003156-21 Sponsor Protocol Number: ETOP_5-12/EORTC_08111 Start Date*: 2014-12-19
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC
    Medical condition: advanced NSCLC
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) IE (Completed) DE (Completed) GB (Completed) AT (Completed) ES (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001111-31 Sponsor Protocol Number: 20101128 Start Date*: 2013-09-09
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Medical condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002337-42 Sponsor Protocol Number: ETOP18-21 Start Date*: 2023-02-02
    Sponsor Name:ETOP IBCSG Partners Foundation
    Full Title: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI
    Medical condition: patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006914-62 Sponsor Protocol Number: BAY 43-9006 / 13266 Start Date*: 2009-04-23
    Sponsor Name:Bayer HealthCare AG, 51368 Leverkusen, Germany
    Full Title: A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2...
    Medical condition: Non-small cell lung carcinoma in patients with predominantly non-squamous cell carcinoma histology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029515 Non-small cell lung cancer recurrent PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Completed) BG (Completed) HU (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003418-10 Sponsor Protocol Number: IRST202.02 Start Date*: 2014-12-17
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS
    Full Title: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS
    Medical condition: Relapsed or refractory DLBCL (DIFFUSE LARGE B CELL LYMPHOMAS) or MCL (MANTLE CELL LYMPHOMAS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000820-20 Sponsor Protocol Number: NVG111-101 Start Date*: 2020-10-30
    Sponsor Name:NovalGen Ltd
    Full Title: AN OPEN-LABEL, PHASE 1/2, FIRST IN HUMAN STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF NVG-111 IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA ...
    Medical condition: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004340-67 Sponsor Protocol Number: EG006/208 Start Date*: 2009-04-21
    Sponsor Name:Ark Therapeutics Limited
    Full Title: A multi-centre, double-blind, randomised, placebo-controlled, phase IIa exploratory study of the effects of Imidapril on body weight and body composition in Non-Small Cell Lung Cancer patients with...
    Medical condition: Cancer Cachexia in Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004851-31 Sponsor Protocol Number: COLINA-MM01/2008 Start Date*: 2008-10-21
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Use of 11C-choline for the evaluation of Multiple Mieloma in staging
    Medical condition: staging of Multiple Mieloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007639-17 Sponsor Protocol Number: UCL/07/158 Start Date*: 2008-09-24
    Sponsor Name:University College London
    Full Title: A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007520-17 Sponsor Protocol Number: 800088NAP2001 Start Date*: 2008-07-25
    Sponsor Name:Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thromb...
    Medical condition: Chemotherapy induced anaemia and chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10039884 Secondary thrombocytopenia LLT
    9.1 10054606 Secondary anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003936-10 Sponsor Protocol Number: D8220C00027 Start Date*: 2022-06-28
    Sponsor Name:AstraZeneca AB
    Full Title: MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia o...
    Medical condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002251-26 Sponsor Protocol Number: CL1-078454-018 Start Date*: 2014-09-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study
    Medical condition: Hodgkin's Disease (HD) , Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008993 Chronic lymphoid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002409-23 Sponsor Protocol Number: CLN-081-001(REZILIENT1) Start Date*: 2020-02-27
    Sponsor Name:Cullinan Oncology Inc.
    Full Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small C...
    Medical condition: Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002142-17 Sponsor Protocol Number: CLL-Frail Start Date*: 2021-11-24
    Sponsor Name:University of Cologne
    Full Title: CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients
    Medical condition: Patients with CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003820-30 Sponsor Protocol Number: HYD-HD85/45-CLL-02 Start Date*: 2016-02-22
    Sponsor Name:HYD Pharma Zrt.
    Full Title: A MULTICENTER, SINGLE ARM, OPEN LABEL, EXPLORATORY PROSPECTIVE PHASE II STUDY TO EXPLORE THE EFFICACY, SAFETY AND TOLERABILITY OF DEUTERIUM DEPLETED WATER IN PREVIOUSLY UNTREATED PATIENTS WITH ASYM...
    Medical condition: Previously untreated patients with asymptomatic chronic lymphocytic leukemia but who are at high risk of progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10060576 Chronic lymphoid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000578-20 Sponsor Protocol Number: CLDK378A2205 Start Date*: 2015-03-16
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024233 Leptomeningeal metastases LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005420-10 Sponsor Protocol Number: D5136C00008 Start Date*: 2015-09-22
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, double-dummy, parallel-group, multicenter, phase IIb study to evaluate the effect of ticagrelor 10 mg and 45 mg bid versus placebo in reducing the number of days with pa...
    Medical condition: Investigating the number of days of pain in SCD patients.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001852-41 Sponsor Protocol Number: GLP1-FMT Start Date*: 2022-09-06
    Sponsor Name:Radboud university medical center
    Full Title: BetaFIT study: Beta cell imaging after Faecal mIcrobiota Transplantation
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004166-10 Sponsor Protocol Number: CO-338-085 Start Date*: 2018-05-04
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Medical condition: Locally Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044412 Transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004749-35 Sponsor Protocol Number: 202000671 Start Date*: 2021-04-08
    Sponsor Name:University Medical Center Groningen
    Full Title: A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapy
    Medical condition: Patients with relapsed/refractory LBCL after 2 prior lines of therapy and qualify for CD19-directed CAR T-cell therapy. Eligibility for CAR T-cell therapy is based on the criteria posed by the Dutc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 07:01:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA